Success Metrics

Clinical Success Rate
77.0%

Based on 241 completed trials

Completion Rate
77%(241/313)
Active Trials
62(13%)
Results Posted
54%(129 trials)
Terminated
72(15%)

Phase Distribution

Ph early_phase_1
8
2%
Ph not_applicable
48
10%
Ph phase_1
64
13%
Ph phase_2
170
36%
Ph phase_3
101
21%
Ph phase_4
68
14%

Phase Distribution

72

Early Stage

170

Mid Stage

169

Late Stage

Phase Distribution459 total trials
Early Phase 1First-in-human
8(1.7%)
Phase 1Safety & dosage
64(13.9%)
Phase 2Efficacy & side effects
170(37.0%)
Phase 3Large-scale testing
101(22.0%)
Phase 4Post-market surveillance
68(14.8%)
N/ANon-phased studies
48(10.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.4%

241 of 333 finished

Non-Completion Rate

27.6%

92 ended early

Currently Active

62

trials recruiting

Total Trials

476

all time

Status Distribution
Active(72)
Completed(241)
Terminated(92)
Other(71)

Detailed Status

Completed241
Terminated72
unknown71
Recruiting40
Active, not recruiting22
Withdrawn20

Development Timeline

Analytics

Development Status

Total Trials
476
Active
62
Success Rate
77.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 18 (1.7%)
Phase 164 (13.9%)
Phase 2170 (37.0%)
Phase 3101 (22.0%)
Phase 468 (14.8%)
N/A48 (10.5%)

Trials by Status

terminated7215%
withdrawn204%
completed24151%
unknown7115%
active_not_recruiting225%
not_yet_recruiting102%
recruiting408%

Recent Activity

Clinical Trials (476)

Showing 20 of 476 trialsScroll for more
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT04544436Phase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Active Not Recruiting
NCT07072585Phase 2

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not Yet Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT00400946Phase 3

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Completed
NCT02166463Phase 3

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Active Not Recruiting
NCT00792948Phase 2

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT04862221Phase 2

TReatment for ImmUne Mediated PathopHysiology

Active Not Recruiting
NCT06970743Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Active Not Recruiting
NCT04548999Phase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Active Not Recruiting
NCT03219359Phase 2

Autologous Stem Cell Transplant for Crohn's Disease

Recruiting
NCT07101445Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Recruiting
NCT04221477Phase 3

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Active Not Recruiting
NCT04408625Phase 1

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Active Not Recruiting
NCT04127578Phase 1

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Active Not Recruiting
NCT07052929Phase 1

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Recruiting
NCT07455396Phase 2

Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma

Not Yet Recruiting
NCT05303792Phase 2

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT05097976Phase 4

Medrol Dosepak for Outpatient Total Knee Arthroplasty

Recruiting
NCT07507643Phase 3

A Study of Methylprednisolone in People Having Liver Surgery

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
476